Texas Childrens Hospital CFTY720D2311
Welcome,         Profile    Billing    Logout  
 3 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tubman, Venee
HOPE Kids 2, NCT04218084 / 2017-000903-26: Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Terminated
3
236
Europe, US, RoW
Voxelotor, Placebo
Pfizer
Sickle Cell Disease
08/23
11/24
SOLACE-Kids, NCT03474965 / 2017-001747-12: Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

Active, not recruiting
2
118
Europe, Canada, US, RoW
Crizanlizumab, SEG101
Novartis Pharmaceuticals
Sickle Cell Disease (SCD)
01/25
01/25
Fuh, Beng R
NCT04657822 / 2020-004225-22: Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Recruiting
4
130
Europe, US, RoW
Crizanlizumab, SEG101
Novartis Pharmaceuticals
Sickle Cell Disease
10/31
10/31
SOLACE-Kids, NCT03474965 / 2017-001747-12: Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

Active, not recruiting
2
118
Europe, Canada, US, RoW
Crizanlizumab, SEG101
Novartis Pharmaceuticals
Sickle Cell Disease (SCD)
01/25
01/25
HOPE-KIDS 1, NCT02850406: Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

Terminated
2
147
Europe, US, RoW
Voxelotor
Pfizer, Pfizer
Sickle Cell Disease
10/23
10/23
AUNT, NCT06071377: Achieving Understanding of the Natural History of Sickle Cell Trait

Recruiting
N/A
1000
US
Biologic Specimen Collection
National Alliance for Sickle Cell Centers, Beam Therapeutics Inc.
Sickle Cell Trait
04/25
04/25
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Iacobas, Ionela
EPIK-L1, NCT05948943: Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Recruiting
2/3
230
Europe, US, RoW
Alpelisib, BYL719, Placebo
Novartis Pharmaceuticals
Lymphatic Malformations
10/27
05/30
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Recruiting
2
205
Europe, Canada, US, RoW
Alpelisib, Placebo
Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
03/24
04/31
Tariq, Batha
SOLACE-Kids, NCT03474965 / 2017-001747-12: Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

Active, not recruiting
2
118
Europe, Canada, US, RoW
Crizanlizumab, SEG101
Novartis Pharmaceuticals
Sickle Cell Disease (SCD)
01/25
01/25

Download Options